Biotech Industry Examiner’s Post

Nice article about the 2024 state of biotech financing. Here are the findings: 1. Series A: $100M+ rounds are becoming common. These rounds often involve in-licensed clinical assets. 2. Focus on Cancer, Immunology, Obesity & Neurology. GLP-1 agonists are the key driver for obesity interest. 3. AI Momentum: Still some big money in AI-driven drug discovery. Tech & biotech investors onboard. 4. CGT Struggles: Funding drop due to remaining manufacturing and scalability issues. ADCs and RLTs gaining favor. 5. Experienced Management: Investors prefer proven teams. De-risking is key. This might not be news to most, but always worth checking personal bias vs. current market trends.

#QuotientTherapeutics, located in #Cambridge, secured an initial $50 million. Leading the round was Flagship Pioneering. The #funds will be used by the business to progress platform #development. Under the #leadership of CEO Geoffrey von Maltzahn, Ph.D., Quotient Therapeutics is an organisation dedicated to methodically #investigating the genetic diversity and #development of the trillions of cells which make up the human body. With the help of its Somatic #Genomics platform, researchers can uncover connections between genes and illness in an array of therapeutic domains, leading to the #development of novel drugs with the potential to treat, prevent, or even reverse #disease. Hao Zhu, MD, from University of Texas Southwestern, Professor Sir Mike Stratton, MD, PhD, Inigo Martincorena, PhD, and Peter Campbell, PhD, from the Wellcome Sanger Institute, and Jacob Rubens, Ph.D., President, and Noubar Afeyan, Chairman of the Strategic #Oversight Board, are among the other co-founders. Apart from von Maltzahn and Rubens, the other executives of Quotient are Simon Brunner, Ph.D., Co-Founder and Head of #Platform; Caroline Fox, M.D., MPH, Senior Vice President, Head of Genetics and Target Discovery; and Scott Hayton, Ph.D., Acting Chief Operating Officer. The first business to #methodically examine the #genetic #diversity and development of the trillions of cells that make up the human body is Quotient Therapeutics. Quotient Therapeutics Geoffrey von Maltzahn Hao Zhu To share your startup story write us on - contact@startuprise.co.uk #quotienttherapeutics #funding #eustartup

Innovation is a transformative force, constantly pushing the boundaries of what’s possible in the world of biotechnological discoveries. Just imagine - expanding immunotherapies to cancer patients, harnessing the power of the 'junk DNA', targeting the molecular machines underlying human disease, making B cells as medicines, progressing monoclonal antibody TREM2... this list goes on and on! Immerse yourself in this fascinating world, and meet Cambridge’s brightest minds and their revolutionary biotech startups, woven together in our latest article: "https://lnkd.in/grnKv4Q4" Featuring: NextPoint Therapeutics, Inc., founded by Gordon Freeman and Xingxing Zang ROME Therapeutics, founded by Rosana Kapeller MOMA Therapeutics, founded by Dorothee Kern, Eva Nogales, Johannes Walter, Timur Yusufzai Be Biopharma, founded by Aleks Radovic-Moreno, David Rawlings, David Steinberg, Lea Hachigian Vigil Neuroscience Theonys, founded by Nick Davis Clade Therapeutics, founded by Chad Cowan, Jim Glasheen, Leandro Vetcher Faze Medicines, founded by J. Paul Taylor, Mike Rosen, Ron Vale, Roy Parker Totus Medicines, founded by Neil Dhawan Transition Bio, Inc., founded by David Weitz, Peter St George-Hyslop, Sarah Teichmann, Tuomas Knowles Catamaran Bio, founded by Branden S. Moriarity, Kevin Pojasek Join us in applauding the efforts of these trailblazing biotech startups in revolutionising the biological technology sector, and pour into this article that captures their inspiring journey! #biotech #innovation #Cambridgestartups #startups #biotechnology #healthcare #pharma #cancerresearch #Genomics #drugdiscovery #healthtech

🔬Switzerland has a long-standing reputation for innovation in pharmaceuticals and biotechnology. A recent article by Labiotech.eu highlights 18 outstanding Swiss biotech companies in areas like gene and cell therapy, cancer treatments and therapies addressing conditions that come with age. We're thrilled to see two of our Switzerland Innovation Park Basel Area - Main Campus residents featured among them: ✨Alentis Therapeutics is a clinical-stage biotechnology company developing innovative therapies targeting claudin-1 positive tumors - a significant unmet medical need. ✨Engimmune Therapeutics is a preclinical company developing next-generation T cell therapies for cancer patients. 👉Read the whole list over here:  https://lnkd.in/gnPbAhQ These are just two examples of the groundbreaking biotech companies that call Switzerland Innovation Park Basel Area their home. Our modern facilities and supportive community provide the perfect platform for companies to develop and thrive. 💡Are you a biotech entrepreneur looking to embark on your own success story? Reach out to us and discover our available workspaces. Roberto Iacone | Rodrigo Vazquez-Lombardi | Lars Nieba | Karin Crisanto | Basel Area Business & Innovation #innovation #biotech #healthcare #pharma #startups

Recent Funding:  OrbiMed, a New York-based life sciences investment firm, raises $4.3 billion in new funds for life science #startup investing. Founded in 1989, the investment firm had made a name for itself as one of the biggest investors in #biotechnology, medtech and healthcare companies. An OrbiMed-backed biotech, Rampart Bioscience (La Jolla, CA), launches with $85M and plans for a new kind of #DNA medicine. Rampart is working on an experimental treatment to compete with Alexion Pharmaceuticals, Inc. Strensiq, which treats the rare disease, hypophosphatasia. Rampart believes its approach can address both delivery and the issue of re-dosability, which may be necessary as #hypophosphatasia progresses, according to the company. Aiolos Bio (San Francisco) has raised $245 million in a Series A financing round on the promise of an #asthma drug that only needs to be taken twice a year. Atlas Venture, Bain Capital Life Sciences, Forbion and Sofinnova Investments led the Series A. The company plans to advance AIO-001 into a Phase 2 trial for patients with moderate-to-severe asthma after promising early results. Aiolos is also studying the monoclonal antibody’s benefits in other conditions, including chronic obstructive #pulmonary disorder and chronic spontaneous #urticaria. Revelation Partners (Sausalito, CA) today announced the closing of its $608 million Fund IV, far surpassing the healthcare #investment firm's initial target of $500 million. Revelation Partners now manages $1.5 billion of committed capital as the firm provides liquidity and flexible capital solutions to investors, companies, limited partners and general partners across all healthcare sub-sectors. MapLight Therapeutics, Inc. (San Francisco) closes $225 Million Series C #funding round to advance pipeline of #CNS therapeutics. Funding will support development of multiple clinical candidates to treat #neurological and #psychiatric disorders, including Phase 2 studies for ML-007C-MA in 2024 in schizophrenia and Alzheimer's disease psychosis. Novo Holdings led a group of top-tier, new investors. M&A, Deals, Partnerships: BioAge Labs (Richmond, CA) has garnered the support of Eli Lilly and Company to run a trial combining a muscle regeneration therapy with the Big Pharma’s tirzepatide for healthier weight loss. While no financial details were disclosed, BioAge will conduct a phase 2 trial of its oral apelin receptor agonist BGE-105 (azelaprag) along with Lilly’s GLP-1/GIP receptor agonist tirzepatide, which is marketed for diabetes as Mounjaro. FDA Approvals: Nkarta, Inc. (San Francisco) wants #celltherapy to go beyond #cancer and has been given the FDA green light to move forward with a CAR NK candidate in human trials for #lupus —news that sent the company’s stock soaring 112%. The allogeneic, CD19-directed CAR NK cell therapy candidate is already being tested out in a phase 1 trial for patients with B-cell malignancies, with top-line data expected next year.

Really interesting article. These are definitely the trends we are seeing in the #USBiotechMarket and will shape #Q4Investment and VC activity 📈 . Can't wait to see these advancements in action! #USBiotech #Immunotherapies #SeriesA #AIML #Radiotherapy #ADCs

Immuneel Therapeutics Pvt. Ltd., a biotech startup based in Bengaluru, has successfully raised Rs 100 crore (approximately $12 million) in an extended Series A funding round. This round was led by Taiba Middle East FZ LLC, bringing Immuneel's total funding to an impressive $40 million. The company's board has approved a special resolution to issue 10 equity shares and 8,164 Series A1 CCPS at Rs 1,22,330 each, according to regulatory filings from the Registrar of Companies. Founded by industry luminary Kiran Mazumdar Shaw, Pulitzer-winning oncologist Siddhartha Mukherjee, and Kush Parwar, Immuneel Therapeutics is at the forefront of developing cutting-edge cell and gene therapies for cancer patients. Their pipeline includes innovative chimeric antigen receptor T-cell (CAR-T) therapies and other cellular immunotherapies. With this latest funding round, Taiba Middle East FZ now holds a 17% stake in Immuneel, valuing the company at approximately Rs 587 crore ($71 million). The newly acquired capital will fuel Immuneel’s growth and expansion, enabling them to scale up research and development, expand clinical trials, and enhance manufacturing capabilities. #ImmuneelTherapeutics #Biotech #BengaluruStartup #SeriesAFunding #FundingAlert #FundraiserAlert #TaibaMiddleEastFZLLC #CellTherapies #GeneTherapies #CancerPatient #ChimericAntigenReceptor #Immunotherapies #BusinessGrowth #BusinessExpansion #ClinalTrials #HealthcareSector #AllBoutCorps

#RI.-based Bolden Therapeutics, Inc. secures $1.5M in pre-seed #convertible note funding. This financing provides important support to enable Bolden to advance its preclinical development of antisense #oligonucleotides to promote #neurogenesis. The round was led by Resolute Venture Partners, and included investments from Slater Technology Fund, Lifespan Vision Ventures, and multiple angel investors. Bolden’s scientific co-founders, Dr. Justin Fallon and Dr. Ashley Webb have identified a key molecular pathway to stimulate neural stem cells to #promote the birth of new neurons (neurogenesis) in the #adult brain. Bolden Therapeutics, Inc., is a #biotechnology company developing first-in-class therapeutics to promote #neurogenesis for the potential treatment of central nervous system illnesses such as Alzheimer’s disease. Bolden Therapeutics Resolute Venture Partners I, LLC Slater Technology Fund Lifespan Vision Ventures Justin Fallon To share your startup story write us on - contact@startuprise.io #boldentherapeutics #funding #startup

The Leading Players: San Diego's Hottest Private Biotech Companies Shaping the Future 🔥 San Diego is heating up as a hotbed for private biotech companies! 🧪💥 With its perfect blend of sunny weather and beautiful beaches, San Diego has become a powerhouse in the biotech industry. 🌞🏖️ Boasting affordable lab spaces, access to biotech investors, and a skilled bio-economy workforce, San Diego rivals other biotech hubs like South San Francisco and Boston. 🌟 Let's take a closer look at nine of the hottest private biotech companies in San Diego: ✨ Artiva Biotherapeutics: Developing game-changing cell therapies for cancer based on natural killer (NK) cells derived from donated umbilical cord blood. ✨ Aspen Neuroscience: Creating personalized cell replacement therapies for neurological diseases using induced pluripotent stem cells. 🧠💪 ✨ Belharra Therapeutics: Revolutionizing drug discovery through their platform that identifies small molecule drug candidates for any protein binding site. ✨ Capstan Therapeutics: Pioneering targeted RNA-based therapies using lipid nanoparticles to reprogram specific cell types. 🎯 ✨ Fate Therapeutics: Defining the future of cellular immunotherapies with their off-the-shelf cell therapy drugs derived from induced pluripotent stem cells. 🌟 ✨ Neurocrine Biosciences: Unlocking breakthrough treatments for neurology, neuroendocrinology, and neuropsychiatry indications. 💡 ✨ Poseida Therapeutics: Harnessing the power of genetic editing platforms to advance cell and gene therapies for cancer and rare diseases. 🧬 ✨ RayzeBio: Revolutionizing solid tumor treatments by utilizing radioactive molecules like actinium-225. 💣💥 ✨ Travere Therapeutics: Breaking barriers with non-immunosuppressive therapies to treat rare kidney and metabolic diseases. 💪 With a booming life sciences industry that employs over 77,000 people, San Diego is truly cementing its position as a leading biotech research destination. 🌐 Curious to learn more about these innovative companies? Check out the full article here: https://lnkd.in/e6SEEtHR 📖👉 https://lnkd.in/dX7DreAY #Biotech #SanDiego #Innovation #LifeSciences #Bioeconomy

Are we on the cusp of a major breakthrough in the European Biotechnology Landscape? 🧪 Our latest article explores the rising potential of early diagnostics in changing health outcomes across Europe! Is the sector set to transcend expectations? Click to find out 👉 https://lnkd.in/eCm9RtB3 Spotlighted in the heart of this story is @MTM Laboratories, a biotech company pushing boundaries in early detection and diagnosis of cervical and other cancers. Based in Heidelberg, Germany, this startup, led by founders Magnus von Knebel Doeberitz and Peter Pack, is championing a proprietary CINtec® technology that could revolutionize early cancer diagnostics.🔬 This is the time to get excited about innovations in health diagnostics. 💉 Stay in the loop with MTM Laboratories and join the conversation about the bright future ahead for European biotech! #Biotech #HealthcareInnovation #EarlyDiagnosis #MTMLaboratories #Startups #EuropeanBiotech #EUStartups #CancerResearch #HealthcareTech